| Title: |
RNASEH2B loss and PARP inhibition in advanced prostate cancer. |
| Authors: |
Carmichael, J; Figueiredo, I; Gurel, B; Beije, N; Yuan, W; Rekowski, J; Seed, G; Carreira, S; Bertan, C; Fenor de La Maza, MDLD; Chandran, K; Neeb, A; Welti, J; Gallagher, L; Bogdan, D; Crespo, M; Riisnaes, R; Ferreira, A; Miranda, S; Lu, J; Shen, MM; Hall, E; Porta, N; Westaby, D; Guo, C; Grochot, R; Lord, CJ; Mateo, J; Sharp, A; de Bono, J |
| Contributors: |
Gurel, Bora; Rekowski, Jan; Seed, George; Carreira, Suzanne; Gallagher, Lewis; Bogdan, Denisa Ioana; Crespo, Mateus; Miranda, Susana; Hall, Emma; Porta, Nuria; Westaby, Daniel; Lord, Christopher; Sharp, Adam; De Bono, Johann |
| Publisher Information: |
AMER SOC CLINICAL INVESTIGATION INC |
| Publication Year: |
2024 |
| Collection: |
The Institute of Cancer Research (ICR): Publications Repository |
| Subject Terms: |
Oncology; Prostate cancer |
| Subject Geographic: |
United States |
| Description: |
BACKGROUNDClinical trials have suggested antitumor activity from PARP inhibition beyond homologous recombination deficiency (HRD). RNASEH2B loss is unrelated to HRD and preclinically sensitizes to PARP inhibition. The current study reports on RNASEH2B protein loss in advanced prostate cancer and its association with RB1 protein loss, clinical outcome, and clonal dynamics during treatment with PARP inhibition in a prospective clinical trial.METHODSWhole tumor biopsies from multiple cohorts of patients with advanced prostate cancer were interrogated using whole-exome sequencing (WES), RNA-Seq (bulk and single nucleus), and IHC for RNASEH2B and RB1. Biopsies from patients treated with olaparib in the TOPARP-A and TOPARP-B clinical trials were used to evaluate RNASEH2B clonal selection during olaparib treatment.RESULTSShallow codeletion of RNASEH2B and adjacent RB1 - colocated at chromosome 13q14 - was common, deep codeletion infrequent, and gene loss associated with lower mRNA expression. In castration-resistant prostate cancer (CRPC) biopsies, RNASEH2B and RB1 mRNA expression correlated, but single nucleus RNA-Seq indicated discordant loss of expression. IHC studies showed that loss of the 2 proteins often occurred independently, arguably due to stochastic second allele loss. Pre- and posttreatment metastatic CRPC (mCRPC) biopsy studies from BRCA1/2 WT tumors, treated on the TOPARP phase II trial, indicated that olaparib eradicated RNASEH2B-loss tumor subclones.CONCLUSIONPARP inhibition may benefit men suffering from mCRPC by eradicating tumor subclones with RNASEH2B loss.TRIAL REGISTRATIONClinicaltrials.gov NCT01682772.FUNDINGAstraZeneca; Cancer Research UK; Medical Research Council; Cancer Research UK; Prostate Cancer UK; Movember Foundation; Prostate Cancer Foundation. |
| Document Type: |
article in journal/newspaper |
| File Description: |
Print-Electronic; application/pdf |
| Language: |
English |
| ISSN: |
1558-8238; 0021-9738 |
| Relation: |
178278; Journal of Clinical Investigation, 2024, pp. e178278 -; https://repository.icr.ac.uk/handle/internal/6345 |
| DOI: |
10.1172/JCI178278 |
| Availability: |
https://doi.org/10.1172/JCI178278; https://repository.icr.ac.uk/handle/internal/6345 |
| Rights: |
http://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.7B33F78C |
| Database: |
BASE |